Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has received an average rating of “Moderate Buy” from the eighteen brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $60.7647.
RARE has been the subject of several recent research reports. JPMorgan Chase & Co. cut their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Wedbush reaffirmed a “neutral” rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. Morgan Stanley lifted their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Canaccord Genuity Group lowered their price target on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their price target for the company from $61.00 to $25.00 in a report on Tuesday, March 24th.
Check Out Our Latest Analysis on Ultragenyx Pharmaceutical
Insider Buying and Selling at Ultragenyx Pharmaceutical
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
Several large investors have recently added to or reduced their stakes in RARE. Assetmark Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares in the last quarter. Leonteq Securities AG lifted its holdings in shares of Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares in the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $39,000. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.
More Ultragenyx Pharmaceutical News
Here are the key news stories impacting Ultragenyx Pharmaceutical this week:
- Positive Sentiment: Crysvita and Dojolvi product sales provide commercial ballast — Q1 product revenues included Crysvita $93M and Dojolvi $18M, showing underlying commercial traction even as total revenue declined. GlobeNewswire: Q1 Results
- Positive Sentiment: Some analysts remain bullish — a recent published price target of $61.18 signals continued upside expectations from parts of the street, which can support buying interest over the medium term. Analyst Price Target
- Neutral Sentiment: FY-2026 revenue guidance given as $730M–$760M (consensus ~$747M) — the range straddles Street expectations, so the top-line outlook is roughly in line with consensus but leaves EPS guidance unclear in public notes. This tempers but does not resolve near-term earnings concerns. Guidance in Press Release
- Neutral Sentiment: Large institutional holdings and recent stake increases from firms like Vanguard and State Street indicate continued institutional interest that may stabilize trading. MarketBeat: Institutional Holdings
- Negative Sentiment: Q1 EPS missed materially: reported loss per share $1.84 vs. consensus ≈ $1.50–$1.55; revenue fell ~2.2% YoY to $136M, underscoring near-term profitability and growth concerns. These misses are the primary negative driver. Zacks: Q1 Loss, Miss
- Negative Sentiment: Insider selling by the CFO (multiple recent sales, latest ~4,683 shares) may be viewed negatively by some investors as a signal of reduced insider conviction or portfolio diversification. SEC Filing: Insider Sale
- Negative Sentiment: Broader sell-side repositioning (e.g., past Goldman downgrade and mixed analyst actions) increases short-term volatility risk as investors digest the earnings gap and guidance nuance. MarketBeat: Analyst Notes
Ultragenyx Pharmaceutical Trading Up 0.8%
Shares of NASDAQ RARE opened at $25.01 on Wednesday. The firm has a 50 day moving average of $22.55 and a 200 day moving average of $26.90. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of -4.28 and a beta of 0.39. Ultragenyx Pharmaceutical has a 12-month low of $18.29 and a 12-month high of $42.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by ($0.34). The business had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.38 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.57) earnings per share. Sell-side analysts predict that Ultragenyx Pharmaceutical will post -4.49 EPS for the current year.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Read More
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
